Cleocin and Hearing loss - a phase IV clinical study of FDA data

Summary:

Hearing loss is reported as a side effect among people who take Cleocin (clindamycin phosphate), especially for people who are male, 60+ old, also take Zometa, and have Toothaches.

The phase IV clinical study analyzes which people have Hearing loss when taking Cleocin. It is created by eHealthMe based on reports of 3,734 people who have side effects when taking Cleocin from the FDA, and is updated regularly.

What is Cleocin?

Cleocin has active ingredients of clindamycin phosphate. It is often used in infection. eHealthMe is studying from 3,940 Cleocin users. Check the latest studies of Cleocin.

What is Hearing loss?

Hearing loss is found to be associated with 1,358 drugs and 2,389 conditions by eHealthMe. Check the latest studies of Hearing loss.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 04, 2026

3,734 people reported to have side effects when taking Cleocin.
Among them, 54 people (1.45%) have Hearing loss.

Among these 54 people:

What is the gender of people who have Hearing loss when taking Cleocin? *

female: 45.28 %
male: 54.72 %

What is the age of people who have Hearing loss when taking Cleocin? *

What are other drugs people take besides Cleocin? *

What are other side effects people have besides Hearing loss? *

Pain: 40 people, 74.07%
Osteomyelitis (infection of bone): 40 people, 74.07%
Cardiac Failure Congestive: 36 people, 66.67%
Enlarged Heart: 36 people, 66.67%
Cataract (clouding of the lens inside the eye): 34 people, 62.96%
Osteonecrosis Of Jaw (death of bone of jaw): 33 people, 61.11%
Weight Decreased: 30 people, 55.56%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 30 people, 55.56%
Spinal Osteoarthritis (joint cartilage loss in spine): 30 people, 55.56%
Bone Disorder: 28 people, 51.85%

What are the existing conditions these people have? *

Toothaches (tooth pain): 13 people, 24.07%
Muscle Spasms (muscle contraction): 11 people, 20.37%
Hypercalcaemia Of Malignancy (elevated calcium (ca+) level in the blood with cancer): 10 people, 18.52%
Multiple Myeloma (cancer of the plasma cells): 10 people, 18.52%
Prostate Cancer Metastatic: 9 people, 16.67%
Hypercalcaemia (elevated calcium (ca+) level in the blood): 5 people, 9.26%
Osteoporosis (bones weak and more likely to break): 4 people, 7.41%
Thrombocytopenia (decrease of platelets in blood): 4 people, 7.41%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 4 people, 7.41%
Depression: 4 people, 7.41%

* Approximation only. Some reports may have incomplete information.

Do you take Cleocin and have Hearing loss?

- Check whether Hearing loss is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cleocin:

Cleocin (3,940 reports)

Hearing loss treatments and more:

Hearing loss (30,352 reports)

Browse all side effects of Cleocin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hearing loss:

Hearing loss (1,358 drugs)

Browse all the conditions that are associated with Hearing loss:

Hearing loss (2,389 conditions)

Related publications that referenced our studies

Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .
Gupta SK, Shwetank B, "Reversible bilateral sensori-neural hearing loss due to olanzapine in a male suffering from bipolar affective disorder", Indian journal of pharmacology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on clindamycin phosphate (the active ingredients of Cleocin) and Cleocin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.